ATE327740T1 - Verwendung von acetylcholinesterasen hemmern zur herstellung eines arzneimittels zur behandlung von funktionellen und/oder organischen schmerzsyndromen - Google Patents

Verwendung von acetylcholinesterasen hemmern zur herstellung eines arzneimittels zur behandlung von funktionellen und/oder organischen schmerzsyndromen

Info

Publication number
ATE327740T1
ATE327740T1 AT99946150T AT99946150T ATE327740T1 AT E327740 T1 ATE327740 T1 AT E327740T1 AT 99946150 T AT99946150 T AT 99946150T AT 99946150 T AT99946150 T AT 99946150T AT E327740 T1 ATE327740 T1 AT E327740T1
Authority
AT
Austria
Prior art keywords
treatment
functional
production
pain syndrome
medicinal product
Prior art date
Application number
AT99946150T
Other languages
English (en)
Inventor
Maria Nicolodi
Federigo Sicuteri
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Application granted granted Critical
Publication of ATE327740T1 publication Critical patent/ATE327740T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99946150T 1998-09-11 1999-09-09 Verwendung von acetylcholinesterasen hemmern zur herstellung eines arzneimittels zur behandlung von funktionellen und/oder organischen schmerzsyndromen ATE327740T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1998FI000208A IT1304904B1 (it) 1998-09-11 1998-09-11 Derivati anticolinesterasici per il trattamento delle sindromidolorose funzionali e/o organiche

Publications (1)

Publication Number Publication Date
ATE327740T1 true ATE327740T1 (de) 2006-06-15

Family

ID=11352669

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99946150T ATE327740T1 (de) 1998-09-11 1999-09-09 Verwendung von acetylcholinesterasen hemmern zur herstellung eines arzneimittels zur behandlung von funktionellen und/oder organischen schmerzsyndromen

Country Status (12)

Country Link
US (1) US6608088B1 (de)
EP (1) EP1112067B1 (de)
JP (1) JP3984787B2 (de)
AT (1) ATE327740T1 (de)
AU (1) AU5861799A (de)
CY (1) CY1105125T1 (de)
DE (1) DE69931640T2 (de)
DK (1) DK1112067T3 (de)
ES (1) ES2265691T3 (de)
IT (1) IT1304904B1 (de)
PT (1) PT1112067E (de)
WO (1) WO2000015205A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1311272E (pt) 2000-03-03 2007-02-28 Eisai R&D Man Co Ltd Novos métodos utilizando inibidores de colinesterase
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
BR0110188A (pt) * 2000-04-21 2003-03-05 Upjohn Co Compostos selecionados para o tratamento de sìndromes de fibromialgia e de fadiga crÈnica
WO2002083141A1 (en) * 2001-04-17 2002-10-24 Pharmacia & Upjohn Company Treatment of fibromyalgia and chronic fatigue syndrome
AT500143A1 (de) * 2004-04-22 2005-11-15 Sanochemia Pharmazeutika Ag Cholinesterase-inhibitoren in liposomen sowie deren herstellung und verwendung
NZ556761A (en) * 2005-01-25 2011-04-29 Galenea Corp Substituted arylamine compounds and their use as 5-HT6 modulators
WO2006086698A2 (en) * 2005-02-11 2006-08-17 Stephen Wills Treating microvasculature diseases with acetyl cholinesterase inhibitors
AU2006232517A1 (en) * 2005-04-04 2006-10-12 Eisai R&D Management Co., Ltd. Dihydropyridine compounds and compositions for headaches
JP2009541368A (ja) * 2006-07-05 2009-11-26 天津和美生物技▲術▼有限公司 鎮痛性5,9−メタノシクロオクタ(b)ピリジン−2−(1H)−オン誘導体、その作成方法と用途
US8012994B1 (en) 2006-09-22 2011-09-06 Sevastyanov Victor V Method for the treatment of sensorineural hearing loss with donepezil hydrochloride (ARICEPT®)
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
CN101668525A (zh) 2007-03-01 2010-03-10 前体生物药物股份公司 谷氨酰胺酰环化酶抑制剂的新用途
EP2865670B1 (de) 2007-04-18 2017-01-11 Probiodrug AG Thioharnstoffderivative als Glutaminylcyclaseinhibitoren
WO2009126931A2 (en) 2008-04-11 2009-10-15 Xvasive, Inc. Combination therapy for bipolar disorder
EP2475428B1 (de) 2009-09-11 2015-07-01 Probiodrug AG Heterocyclische derivate als glutaminylcyclase-hemmer
JP6082250B2 (ja) 2010-02-09 2017-02-15 ザ・ジョンズ・ホプキンス・ユニバーシティー 認知機能を改善するための方法および組成物
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
DK2686313T3 (en) 2011-03-16 2016-05-02 Probiodrug Ag Benzimidazole derivatives as inhibitors of glutaminyl cyclase
JP2015078129A (ja) * 2012-02-01 2015-04-23 株式会社新日本科学 ドネペジルを含む線維筋痛症の治療剤
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
EP2968220B1 (de) 2013-03-15 2021-05-05 Agenebio, Inc. Verfahren und zusammensetzungen zur verbesserung von kognitiven funktionen
CA2986598C (en) 2015-05-22 2023-09-26 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5010083A (en) 1988-03-28 1991-04-23 Hoechst-Roussel Pharmaceuticals, Inc. 2,6-methano-1,3-benzodiazocine compounds which have useful pharmaceutical utility
DE3927049A1 (de) 1989-08-16 1991-02-21 Sandoz Ag Halogenalkyl-phenyl-ketone und deren hydrate, ihre herstellung und verwendung
US5336675A (en) 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
GB9606736D0 (en) 1996-02-19 1996-06-05 Shire International Licensing Therapeutic method
WO1999008672A1 (en) 1997-08-15 1999-02-25 Shire International Licensing Bv Use of cholinesterase inhibitor for treating diseases associated with proteolytic enzyme activity

Also Published As

Publication number Publication date
JP3984787B2 (ja) 2007-10-03
IT1304904B1 (it) 2001-04-05
WO2000015205A3 (en) 2000-08-24
ES2265691T3 (es) 2007-02-16
CY1105125T1 (el) 2009-11-04
WO2000015205A2 (en) 2000-03-23
JP2002524498A (ja) 2002-08-06
DE69931640D1 (de) 2006-07-06
EP1112067A2 (de) 2001-07-04
DK1112067T3 (da) 2006-09-04
ITFI980208A1 (it) 2000-03-11
PT1112067E (pt) 2006-09-29
ITFI980208A0 (it) 1998-09-11
AU5861799A (en) 2000-04-03
US6608088B1 (en) 2003-08-19
EP1112067B1 (de) 2006-05-31
DE69931640T2 (de) 2007-03-08

Similar Documents

Publication Publication Date Title
ATE327740T1 (de) Verwendung von acetylcholinesterasen hemmern zur herstellung eines arzneimittels zur behandlung von funktionellen und/oder organischen schmerzsyndromen
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE69523745D1 (de) Gel zur behandlung von hauterkrankungen und zur desinfizierung von haut
DK0801564T3 (da) Anvendelse af nebivolol som et antiatherogent middel
DE69805202D1 (de) Verwendung von benzhydrylsulfinylderivaten zur behandlung der schläfigkeit medikamentösen ursprungs
DE69827651D1 (de) Verwendung von tempol zur behandlung von essentiellem hochdruck
DE69526937T2 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
DE69713620D1 (de) Verwendung von arachidonsäure und/oder docohexaensäure zur herstellung eines arzneimittels zur behandlung von dyspraxia
DE69825286D1 (de) Verwendung von cholinesterasehemmern zur behandlung von aufmerksamkeitsmangel-störungen
ATE318141T1 (de) Verwendung von taurolidin oder taurultam zur herstellung eines arzneimittels zur vorbeugung von metastasen
DE69825440D1 (de) VERWENDUNG VON TAUROLIDINE ZUR Herstellung eines Arzneimittels zur BEHANDLUNG VON LEUKÄMIEN
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE214605T1 (de) Verwendung von eliprodil zur herstellung eines arzneimittels zur behandlung von ischämischen störungen der retina oder des sehnervs
HUP0000756A2 (hu) Levobupivakain vagy ropivakain alkalmazása migrén kezelésére alkalmas gyógyszerkészítmények előállítására
DE69424563D1 (de) Verwendung von dimeticon zur herstellung eines arzneimittels zur behandlung von aphthen und stomatitis
ATE247956T1 (de) Verwendung von modafinil zur herstellung eines arzneimittels zur behandlung von vigilanzstörungen im zusammenhang mit myopathien
HUP0001913A2 (hu) Pramipexole alkalmazása állandóan mozgó láb szindróma kezelésére szolgáló gyógyszerkészítmények előállítására
DE69720064D1 (de) Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen
DE60220825D1 (de) Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
DE69919578D1 (de) VERWENDUNG von NIEDERMOLEKULAREM HEPARIN zur Behandlung und/oder Prophylaxe motoneuronaler Krankheiten
ATE275949T1 (de) Verwendung von diminazen-di-aceturat und/oder pentamidin zur behandlung von malaria
DE50012667D1 (de) Verwendung von 2-amino-3,4-dihydro-chinazolinen zur herstellung eines medikaments zur behandlung oder prophylaxe von ischämischen zuständen
ATE236625T1 (de) Verwendung von 5ht2a und 5ht2a/c antagonisten zur herstellung von arzneimitteln zur behandlung des schnarchens und des herhoten widerstandes der oberen luftwege
ATE275420T1 (de) Verwendung von cysteinprotease inhibitoren zur herstellung eines arzneimittels zur vorgbeugung und behandlung von gehirngewebezerrütung infolge hypertensive enzephalopathie oder encephalothlipsis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1112067

Country of ref document: EP

EEIH Change in the person of patent owner